BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16496415)

  • 1. Loss of PTEN is associated with progression to androgen independence.
    Bertram J; Peacock JW; Fazli L; Mui AL; Chung SW; Cox ME; Monia B; Gleave ME; Ong CJ
    Prostate; 2006 Jun; 66(9):895-902. PubMed ID: 16496415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.
    Wu Z; Conaway M; Gioeli D; Weber MJ; Theodorescu D
    Prostate; 2006 Jul; 66(10):1114-23. PubMed ID: 16637073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
    Miyake H; Pollak M; Gleave ME
    Cancer Res; 2000 Jun; 60(11):3058-64. PubMed ID: 10850457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors.
    Kiyama S; Morrison K; Zellweger T; Akbari M; Cox M; Yu D; Miyake H; Gleave ME
    Cancer Res; 2003 Jul; 63(13):3575-84. PubMed ID: 12839944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer.
    Mulholland DJ; Dedhar S; Wu H; Nelson CC
    Oncogene; 2006 Jan; 25(3):329-37. PubMed ID: 16421604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice.
    Gao H; Ouyang X; Banach-Petrosky WA; Shen MM; Abate-Shen C
    Cancer Res; 2006 Aug; 66(16):7929-33. PubMed ID: 16912166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
    Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P
    Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H; Nelson C; Rennie PS; Gleave ME
    Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.
    Miyake H; Tolcher A; Gleave ME
    Cancer Res; 1999 Aug; 59(16):4030-4. PubMed ID: 10463603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
    Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
    Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
    Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells.
    Cornforth AN; Davis JS; Khanifar E; Nastiuk KL; Krolewski JJ
    Oncogene; 2008 Jul; 27(32):4422-33. PubMed ID: 18391984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.
    Jiao J; Wang S; Qiao R; Vivanco I; Watson PA; Sawyers CL; Wu H
    Cancer Res; 2007 Jul; 67(13):6083-91. PubMed ID: 17616663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model.
    Miyake H; Monia BP; Gleave ME
    Int J Cancer; 2000 Jun; 86(6):855-62. PubMed ID: 10842201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice.
    Banach-Petrosky W; Jessen WJ; Ouyang X; Gao H; Rao J; Quinn J; Aronow BJ; Abate-Shen C
    Cancer Res; 2007 Oct; 67(19):9089-96. PubMed ID: 17909013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state.
    Murillo H; Huang H; Schmidt LJ; Smith DI; Tindall DJ
    Endocrinology; 2001 Nov; 142(11):4795-805. PubMed ID: 11606446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
    Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.
    Miyake H; Nelson C; Rennie PS; Gleave ME
    Cancer Res; 2000 Jan; 60(1):170-6. PubMed ID: 10646870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gata3 antagonizes cancer progression in Pten-deficient prostates.
    Nguyen AH; Tremblay M; Haigh K; Koumakpayi IH; Paquet M; Pandolfi PP; Mes-Masson AM; Saad F; Haigh JJ; Bouchard M
    Hum Mol Genet; 2013 Jun; 22(12):2400-10. PubMed ID: 23428429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.
    Narayanan NK; Nargi D; Randolph C; Narayanan BA
    Int J Cancer; 2009 Jul; 125(1):1-8. PubMed ID: 19326431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.